200 related articles for article (PubMed ID: 22553982)
1. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma.
Barney BM; Olivier KR; Miller RC; Haddock MG
Radiat Oncol; 2012 May; 7():67. PubMed ID: 22553982
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Gkika E; Hallauer L; Kirste S; Adebahr S; Bartl N; Neeff HP; Fritsch R; Brass V; Nestle U; Grosu AL; Brunner TB
BMC Cancer; 2017 Nov; 17(1):781. PubMed ID: 29162055
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
Barney BM; Olivier KR; Macdonald OK; Fong de Los Santos LE; Miller RC; Haddock MG
Am J Clin Oncol; 2012 Dec; 35(6):537-42. PubMed ID: 21659830
[TBL] [Abstract][Full Text] [Related]
5. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
Kopek N; Holt MI; Hansen AT; Høyer M
Radiother Oncol; 2010 Jan; 94(1):47-52. PubMed ID: 19963295
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Brunner TB; Blanck O; Lewitzki V; Abbasi-Senger N; Momm F; Riesterer O; Duma MN; Wachter S; Baus W; Gerum S; Guckenberger M; Gkika E
Radiother Oncol; 2019 Mar; 132():42-47. PubMed ID: 30825968
[TBL] [Abstract][Full Text] [Related]
9. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.
Zeng ZC; Tang ZY; Fan J; Zhou J; Qin LX; Ye SL; Sun HC; Wang BL; Li D; Wang JH; Zeng MS; Guo W; Tan YS
Cancer J; 2006; 12(2):113-22. PubMed ID: 16630402
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy.
Dewas S; Bibault JE; Mirabel X; Fumagalli I; Kramar A; Jarraya H; Lacornerie T; Dewas-Vautravers C; Lartigau E
Radiat Oncol; 2012 Oct; 7():166. PubMed ID: 23050794
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.
Sandler KA; Veruttipong D; Agopian VG; Finn RS; Hong JC; Kaldas FM; Sadeghi S; Busuttil RW; Lee P
Adv Radiat Oncol; 2016; 1(4):237-243. PubMed ID: 28740893
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
13. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
[TBL] [Abstract][Full Text] [Related]
14. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma.
Zhang XX; Ma HB; Li TH; Huang B; Jia NY; Meng Y
Clin Transl Oncol; 2023 Mar; 25(3):731-738. PubMed ID: 36401766
[TBL] [Abstract][Full Text] [Related]
15. Single center experience using stereotactic body radiation therapy (SBRT) on orthotopic liver transplant protocol for unresectable cholangiocarcinoma.
Wu TC; Deng J; Chu FI; Sadeghi S; Finn R; Agopian VG; Lee P; Raldow AC
HPB (Oxford); 2024 Mar; 26(3):444-450. PubMed ID: 38142182
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review.
Lee J; Yoon WS; Koom WS; Rim CH
Strahlenther Onkol; 2019 Feb; 195(2):93-102. PubMed ID: 30206644
[TBL] [Abstract][Full Text] [Related]
18. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors.
Ibarra RA; Rojas D; Snyder L; Yao M; Fabien J; Milano M; Katz A; Goodman K; Stephans K; El-Gazzaz G; Aucejo F; Miller C; Fung J; Lo S; Machtay M; Sanabria JR
Acta Oncol; 2012 May; 51(5):575-83. PubMed ID: 22263926
[TBL] [Abstract][Full Text] [Related]
19. Repeated SBRT for in- and out-of-field recurrences in the liver.
Gkika E; Strouthos I; Kirste S; Adebahr S; Schultheiss M; Bettinger D; Fritsch R; Brass V; Maruschke L; Neeff HP; Lang SA; Nestle U; Grosu AL; Brunner TB
Strahlenther Onkol; 2019 Mar; 195(3):246-253. PubMed ID: 30353350
[TBL] [Abstract][Full Text] [Related]
20. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.
de Jong MC; Marques H; Clary BM; Bauer TW; Marsh JW; Ribero D; Majno P; Hatzaras I; Walters DM; Barbas AS; Mega R; Schulick RD; Choti MA; Geller DA; Barroso E; Mentha G; Capussotti L; Pawlik TM
Cancer; 2012 Oct; 118(19):4737-47. PubMed ID: 22415526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
